Date：28 July (Thursday) 10:40 – 12:10 (GMT+8)
Venue：701EF, TaiNEX2, Taipei + Online event platform
As the acute phase of the pandemic winds down, the initial round of rapidly developed and deployed COVID-19 vaccines will make way for a newer generation of vaccines that promise better potency, an improved safety profile, and more convenient logistical requirements. Meanwhile the quest for a ‘universal vaccine’ that provides protection from all variants is well underway, with Taiwan researchers in particular reporting promising results. And with still only a handful of antibody and antiviral treatments approved, including Pfizer’s Paxlovid and Merk’s Lagevrio, the pipeline is bursting with almost 100 more in clinical development. The threat of the virus developing resistance to drug treatment is real, and with mutations such as Omicron continuing to emerge, a strong and ongoing pipeline of new COVID-19 drugs will be essential for years to come. We invite you to join us in this important session as our panel of public health experts and drug researchers report on the latest COVID-19 vaccine and antiviral developments.